Avalo Therapeutics (AVTX) Asset Writedowns and Impairment (2018)
Avalo Therapeutics posted quarterly Asset Writedowns and Impairment of $159687.0 for Q3 2018, down 90.62% on a QoQ basis from $1.7 million in Q2 2018.
Avalo Therapeutics (AVTX) has 1 years of Asset Writedowns and Impairment data on file, last reported at $159687.0 in Q3 2018.
- For the quarter ending Q3 2018, Asset Writedowns and Impairment changed N/A year-over-year to $159687.0; the trailing twelve-month figure through Dec 2019 stood at $159687.0 (down 91.42% YoY), and the FY2019 full-year result was $1.4 million, down 22.16% from the prior year.
- Asset Writedowns and Impairment for Q3 2018 stood at $159687.0, down from $1.7 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $1.7 million in Q2 2018 and bottomed at $159687.0 in Q3 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 159,687.00 |
| Sep 30, 2018 | 159,687.00 |
| Jun 30, 2018 | 1.70 Mn |
| Jun 30, 2018 | 1.70 Mn |